Redhill Biopharma Ltd., of Tel-Aviv, Israel, said a phase II study evaluating Yeliva (ABC294640), an orally-administered, sphingosine kinase-2 (SK2) selective inhibitor, in patients with advanced hepatocellular carcinoma (HCC) has been initiated, with enrollment expected to start shortly. It will be conducted at the Medical University of South Carolina Hollings Cancer Center (MUSC) and additional clinical centers in the U.S. and is supported by a $1.8 million grant from the National Cancer Institute awarded to MUSC.